JP2021522271A - 虚弱および加齢を改善するための方法 - Google Patents
虚弱および加齢を改善するための方法 Download PDFInfo
- Publication number
- JP2021522271A JP2021522271A JP2020560271A JP2020560271A JP2021522271A JP 2021522271 A JP2021522271 A JP 2021522271A JP 2020560271 A JP2020560271 A JP 2020560271A JP 2020560271 A JP2020560271 A JP 2020560271A JP 2021522271 A JP2021522271 A JP 2021522271A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- age
- frailty
- tlr5 agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003549 asthenia Diseases 0.000 title claims abstract description 97
- 208000036119 Frailty Diseases 0.000 title claims abstract description 96
- 230000032683 aging Effects 0.000 title claims description 82
- 238000000034 method Methods 0.000 claims abstract description 117
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 105
- 108010040721 Flagellin Proteins 0.000 claims abstract description 92
- 239000000556 agonist Substances 0.000 claims abstract description 84
- 208000035475 disorder Diseases 0.000 claims abstract description 54
- 201000010099 disease Diseases 0.000 claims abstract description 51
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims abstract 23
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims abstract 23
- 238000011282 treatment Methods 0.000 claims description 81
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 201000011510 cancer Diseases 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 229920001184 polypeptide Polymers 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 230000007547 defect Effects 0.000 claims description 25
- 206010061218 Inflammation Diseases 0.000 claims description 23
- 230000004054 inflammatory process Effects 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 20
- 230000001717 pathogenic effect Effects 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 13
- 210000003743 erythrocyte Anatomy 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 102000001554 Hemoglobins Human genes 0.000 claims description 12
- 108010054147 Hemoglobins Proteins 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 238000009825 accumulation Methods 0.000 claims description 11
- 230000002159 abnormal effect Effects 0.000 claims description 10
- 230000001771 impaired effect Effects 0.000 claims description 10
- 210000003491 skin Anatomy 0.000 claims description 10
- 208000010200 Cockayne syndrome Diseases 0.000 claims description 9
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 claims description 9
- 208000007932 Progeria Diseases 0.000 claims description 9
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- -1 anthracycline Substances 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000005692 Bloom Syndrome Diseases 0.000 claims description 6
- 206010052465 Congenital poikiloderma Diseases 0.000 claims description 6
- 208000000791 Rothmund-Thomson syndrome Diseases 0.000 claims description 6
- 201000011032 Werner Syndrome Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 230000001172 regenerating effect Effects 0.000 claims description 6
- 201000004569 Blindness Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 230000010094 cellular senescence Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000000440 neutrophil Anatomy 0.000 claims description 5
- 230000002028 premature Effects 0.000 claims description 5
- 208000034979 restrictive dermopathy Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 230000035487 diastolic blood pressure Effects 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 4
- 238000005534 hematocrit Methods 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 208000001076 sarcopenia Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 208000007474 aortic aneurysm Diseases 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 210000002510 keratinocyte Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 230000008085 renal dysfunction Effects 0.000 claims description 3
- 230000035488 systolic blood pressure Effects 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000032544 Cicatrix Diseases 0.000 claims description 2
- 230000000970 DNA cross-linking effect Effects 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 206010019909 Hernia Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010049565 Muscle fatigue Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 201000004458 Myoma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 241000519995 Stachys sylvatica Species 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000004252 chorionic villi Anatomy 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 208000024558 digestive system cancer Diseases 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 208000000069 hyperpigmentation Diseases 0.000 claims description 2
- 230000003810 hyperpigmentation Effects 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000025189 neoplasm of testis Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 230000037387 scars Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 239000003277 telomerase inhibitor Substances 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 230000006444 vascular growth Effects 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 229940125431 BRAF inhibitor Drugs 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims 1
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 201000004435 urinary system cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 41
- 238000010586 diagram Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 61
- 230000000694 effects Effects 0.000 description 37
- 230000004083 survival effect Effects 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 28
- 150000001413 amino acids Chemical group 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000036541 health Effects 0.000 description 16
- 230000007423 decrease Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 12
- 241000282412 Homo Species 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000607142 Salmonella Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000002689 Toll-like receptor Human genes 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 230000006020 chronic inflammation Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 108010079458 CBLB502 Proteins 0.000 description 5
- 241000871495 Heeria argentea Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 229950009493 entolimod Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000032677 cell aging Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000003716 rejuvenation Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003495 flagella Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940124302 mTOR inhibitor Drugs 0.000 description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 230000036558 skin tension Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 2
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004982 adipose tissue macrophage Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108010040473 pneumococcal surface protein A Proteins 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101710205608 Flagellin 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101001047515 Homo sapiens Lethal(2) giant larvae protein homolog 1 Proteins 0.000 description 1
- 101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 description 1
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100022956 Lethal(2) giant larvae protein homolog 1 Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101150100944 Nos2 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 101150088826 arg1 gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000000220 brain stem cancer Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000007380 inflammaging Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108091005434 innate immune receptors Proteins 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
【選択図】図1
Description
関連出願の相互参照
電子的に提出されたテキストファイルの説明
虚弱および虚弱指数
加齢性疾患および障害
加速された加齢(癌およびプロセロイド症候群)
生存期間
対象
TLR5アゴニストおよびその誘導体
MAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNGPKEATVGDLKSSFKNVTGYDTYAAGADKYRVDINSGAVVTDAAAPDKVYVNAANGQLTTDDAENNTAVDLFKTTKSTAGTAEAKAIAGAIKGGKEGDTFDYKGVTFTIDTKTGDDGNGKVSTTINGEKVTLTVADIATGAADVNAATLQSSKNVYTSVVNGQFTFDDKTKNESAKLSDLEANNAVKGESKITVNGAEYTANATGDKITLAGKTMFIDKTASGVSTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号27)。
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号1)。
CBLB502−S33ML(国際公開第2016/019034号の配列番号35)
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG(配列番号2);
CBLB502−485CT(CBLB533、国際公開第2016/019034号の配列番号71)
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGLVPRGSHHHHHHG(配列番号3);
CBLB502−S33MX(CBLB543、国際公開第2016/019034号の配列番号150)
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAADGISIAQTTEGALNEINNNLQRVRELSVQATAGANADAALKAIQAEIQQRLEEIDRVSQQTQAAAVKVLSQDNAMAIQVGANDGAAITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSQMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG(配列番号4);
CBLB502−S33(国際公開第2016/019034号の配列番号17)
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号5);および
変異体33ML(国際公開第2016/019034号の配列番号42)
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG(配列番号6)。
国際公開第2016/019134号の配列番号243
MGHHHHHHSGMEEFNMRINTNVAAMNTYSRLTAANTAKSNSLAKLSSGLRINKAGDDAAGLAISEKMKSQIGGLTQAKRNAQDGISLVQTAEGALNETHSILERMRDLAVQGSNGTLTSSDRGSINKELKALHQELTRISNTTEFNTQKLFSQTKQKSVTFTFQIGANAGQTLSVAITAMSGEALLVSTDAKFSLNAAGTNAGAMIKSIDAAIAKVSDQRADLGAVQNRLEHTINNLTATNENLSDANSRIRDVDMAEEMMTFTKSNILSQAATSMLAQANAMPNSVLNLLQG(配列番号7);
国際公開第2016/019134号の配列番号244
MGHHHHHHSGMRINHNISALNAWRNIDQTQYSMSKTLERLSSGLRINRAGDDAAGLAISEKMRGQIKGLNMAIKNAQDAISLIQTAEGALTEVHSILQRMRELAVQAASDTNTNVDREQIQKEIDQLREEIDRIARTTEFNTKKLLDGKLEGFRSQVDAKVVTGGNINVQLGTVSSKAVEGTYVIEVGAAERAIMVVDAAIHRVSTARAALGAIQNRLEHTISNLGVAAENLTAAESRIRDADMAKEMMEFTKQQILLQSSMAMLAQSNTLPQNVLQLMR(配列番号8);
国際公開第2016/019134号の配列番号245
MGHHHHHHSGLNMAIKNAQDAISLIQTAEGALTEVHSILQRMRELAVQAASDTNTNVDREQIQKEIDQLREEIDRIARTTEFNTKKLLDGKLEGFRSQVDAKVVTGGNINVQLGTVSSKAVEGTYVIEVGAAERAIMVVDAAIHRVSTARAALGAIQNRLEHTISNLG(配列番号9);
国際公開第2016/019134号の配列番号246
MGHHHHHHSGMSLRINNNIEALNAWRALNSTSNALQKSMEKLSSGLRINRAGDDAAGLAISEKLRAQIRGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAITTELNQLFNEIDRIAGATEFNTKNLLAVSTGLVVTLQVGANAGQVIAFTIDNAGTASLGLSSADLAINDNASASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLGIASENLSASESRIRDVDMAAEMMNFTKNQILQQAGVAILAQANQAPQAVLQLLR(配列番号10);
国際公開第2016/019134号の配列番号247
MGHHHHHHSGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAITTELNQLFNEIDRIAGATEFNTKNLLAVSTGLVVTLQVGANAGQVIAFTIDNAGTASLGLSSADLAINDNASASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLG(配列番号11);
国際公開第2016/019134号の配列番号248
MGHHHHHHSGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAITTELNQLFNEIDRIAGATEFNTKNLLAAGTASLGLSSADLAINDNASASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLG(配列番号12);
国際公開第2016/019134号の配列番号249
MGHHHHHHSASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLGPDGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISAITTELNQLFNEIDRIA(配列番号13);
国際公開第2016/019134号の配列番号250
MGHHHHHHSNNQDISAITTELNQLFNEIDRIAGATGSGGLSEIQNILQRMRELGVQAANGTLNGGSASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLG(配列番号14);
国際公開第2016/019134号の配列番号251
MGHHHHHHSGLAQASRNAQDAISIAQTAEGALDETQSILQRVRELGVQGANGTLTADDINALQAEVDQLIAEIDRIAGATEFNTQNLLDGSFTTKAFQVGANSGQNMTLTIGKMDTTTLGLSSADLAINDNAFANGAISTVDSALQKVSAERAKLGAIQNRLEHTIANLG(配列番号15);および
国際公開第2016/019134号の配列番号252
MGHHHHHHSGLAQASRQAQDAISIAQTAEGALDETQSILQRVRELGVQGADGTLTADDIDALQAEVDQLIAEIDRIAGATEFATQKLLDGSFTTKAFQVGAASGQDVTLTIGKVDTTTLGLSSADLAIDSAAFADGAISTVDSALQKVSAERAKLGAIQNRLEHTIAQLG(配列番号16)。
国際公開第2006/069198号の配列番号10
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNL(配列番号17);
国際公開第2006/069198号の配列番号12
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号17);
国際公開第2006/069198号の配列番号30
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号17);
国際公開第2006/069198号の配列番号32
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号17);
国際公開第2006/069198号の配列番号34
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号17);
国際公開第2006/069198号の配列番号36
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号17);
国際公開第2006/069198号の配列番号38
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNL(配列番号17);
国際公開第2006/069198号の配列番号40
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNL(配列番号17);
国際公開第2006/069198号の配列番号42
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号17);および
国際公開第2006/069198号の配列番号44
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQIPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR(配列番号17)。
投与量、投与および医薬配合物
キット
定義
実施例
実施例1:TLR5の薬理学的刺激は、生活の質を改善し虚弱を減少させる
実施例2:虚弱指数を改善するためのエントリモドの投与。
実施例3:虚弱指数を改善するための患者へのエントリモドの投与。
実施例4:白血病治療を受けた小児患者へのエントリモドの投与。
Claims (52)
- 患者において虚弱を治療または防止する方法であって、
(a)虚弱の治療または防止を所望するまたは必要としている患者を特定することと、
(b)前記患者に組換えTLR5アゴニストを投与することであって、前記TLR5アゴニストが、病原性タンパク質抗原に融合されない、投与すること
を含む、方法。 - 虚弱が、主要な生理学的機能における欠陥の蓄積、再生能力の低下、損なわれた創傷治癒および/または加齢性疾患または障害の増大されたリスクを含む、請求項1に記載の方法。
- 虚弱が、生理学的虚弱指数に従って測定される、請求項1または2のいずれか一項に記載の方法。
- 前記生理学的虚弱指数(PFI)が、握力、収縮期血圧、拡張期血圧、血流量、血中好中球の数、血中好中球の割合、血中単球の数、血中単球の割合、リンパ球の数、赤血球の数、ヘモグロビン値、ヘマトクリット値、平均赤血球容積、平均赤血球ヘモグロビン値、平均赤血球ヘモグロビン濃度およびケラチノサイト由来サイトカインレベルから選択される1つ以上のパラメータの評価を含む、請求項3に記載の方法。
- 前記TLR5アゴニストが、フラジェリンまたはその誘導体である、請求項1〜4のいずれか一項に記載の方法。
- 前記TLR5アゴニストが、配列番号1に対して少なくとも95%の配列同一性を有するアミノ酸配列を有するポリペプチドを含む、請求項5に記載の方法。
- 前記TLR5アゴニストが、配列番号1であるアミノ酸配列を有するポリペプチドを含む、請求項6に記載の方法。
- 前記TLR5アゴニストが、配列番号2〜27の1つに対して少なくとも95%の配列同一性を有するアミノ酸配列を有するポリペプチドを含む、請求項5に記載の方法。
- 前記TLR5アゴニストが、配列番号2〜27の1つのアミノ酸配列を有するポリペプチドを含む、請求項8に記載の方法。
- 前記患者の生理学的虚弱指数が、約25%〜約75%低下される、請求項1〜9のいずれか一項に記載の方法。
- 前記患者の生理学的虚弱指数が、少なくとも約75%、または約50%、または約35%、または約25%低下される、請求項10に記載の方法。
- 前記虚弱が、加齢と関連する、請求項10に記載の方法。
- 前記患者が、中年である、請求項1〜12のいずれか一項に記載の方法。
- 前記患者が、約36歳〜約55歳である、請求項13に記載の方法。
- 前記患者が、高齢である、請求項1〜14のいずれか一項に記載の方法。
- 前記患者が、約56歳〜約85歳である、請求項15に記載の方法。
- 前記患者の生物学的性別が、男性である、請求項1〜16のいずれか一項に記載の方法。
- 前記患者の生物学的性別が、女性である、請求項1〜17のいずれか一項に記載の方法。
- 患者において加齢性疾患または障害を治療または防止する方法であって、
(a)加齢性疾患または障害の治療または防止を所望するかまたは必要としている患者を特定することと、
(b)前記患者に組換えTLR5アゴニストを投与することであって、前記TLR5アゴニストが、病原性タンパク質抗原に融合されない、投与すること
を含む、方法。 - 前記加齢性疾患または障害が、増大された細胞老化を特徴とする、請求項19に記載の方法。
- 前記加齢性疾患または障害が、加速された加齢、循環器疾患、脳血管障害、末梢血管疾患、心臓拡張機能障害、良性前立腺肥大症、大動脈瘤、肺気腫、アテローム性動脈硬化症、糖尿病、肺線維症、失明、認知症、アルツハイマー病、腎機能障害、変形性関節症、低悪性度の慢性無菌炎症、椎間板ヘルニア、虚弱、脱毛、難聴、視力喪失、筋肉疲労、皮膚の状態、皮膚母斑、しわの多い皮膚、色素沈着過剰、傷跡、ケロイド、酒さ、白斑、尋常性魚鱗癬、皮膚筋炎、日光角化症、およびサルコペニアから選択される、請求項19または20に記載の方法。
- 前記加齢性疾患または障害が、加速された加齢である、請求項21に記載の方法。
- 前記加速された加齢が、早老症候群、またはその症状である、請求項22に記載の方法。
- 前記早老症が、ハッチンソン−ギルフォード早老症候群(HGPS)、ウェルナー症候群(WS)、ブルーム症候群(BS)、ロスムンド・トムソン症候群(RTS)、コケイン症候群(CS)、色素性乾皮症(XP)、トリコチオジストロフィー(TTD)、色素性乾皮症−コケイン症候群(XP−CS)の合併症、および拘束性皮膚障害(RD)から選択される、請求項23に記載の方法。
- 前記加速された加齢が、癌または癌治療によって誘発される、請求項22に記載の方法。
- 前記癌治療が、放射線療法、ホルモン療法、チロシンキナーゼ阻害剤、アントラサイクリン、アルキル化剤、トポイソメラーゼ阻害剤、代謝拮抗剤/細胞毒性薬物、BRAF阻害剤、抗腫瘍抗生物質、イソキノロリンアルカロイド、Bcl−2阻害剤、造血細胞移植(HCT)、テロメラーゼ阻害剤、ヌクレオシドアナログ逆転写酵素阻害剤、DNA架橋剤、リボヌクレオチドレダクターゼ阻害剤、微小管阻害剤、およびmiRNAの1つ以上から選択される、請求項25に記載の方法。
- 前記患者が、以前に癌に罹患していた、請求項25または26に記載の方法。
- 前記患者が、癌生存者である、請求項27に記載の方法。
- 前記癌生存者が、癌治療を完了しておりかつ活動性疾患の明らかなエビデンスを有しない、請求項28に記載の方法。
- 前記癌が、基底細胞癌、胆道癌;膀胱癌;骨肉腫;脳および中枢神経系の癌;乳癌;腹膜癌;子宮頸癌;絨毛癌;結腸直腸癌;結合組織癌;消化器系癌;子宮内膜癌;食道癌;眼癌;頭頸部癌;胃癌(消化器癌を含む);膠芽腫;肝癌;肝細胞癌;上皮内新生物;腎臓癌または腎癌;喉頭癌;白血病;肝癌;肺癌(例えば、小細胞肺癌、非小細胞肺癌、肺腺癌、および肺扁平上皮癌);黒色腫;骨髄腫;神経芽細胞腫;口腔癌(唇、舌、口、および咽頭);卵巣癌;膵癌;前立腺癌;網膜芽細胞腫;横紋筋肉腫;直腸癌;呼吸器系癌;唾液腺癌;肉腫;皮膚癌;扁平上皮癌;胃癌;精巣腫瘍;甲状腺癌;子宮癌または子宮内膜癌;泌尿器系癌;外陰癌;ホジキンリンパ腫および非ホジキンリンパ腫を含むリンパ腫、ならびにB細胞リンパ腫(低悪性度/濾胞性非ホジキンリンパ腫(NHL)を含む);小リンパ球性(SL)NHL;中悪性度/濾胞性NHL;中悪性度びまん性NHL;高悪性度免疫芽球性NHL;高悪性度リンパ芽球性NHL;高悪性度非切断小細胞NHL;巨大腫瘤性NHL;マントル細胞リンパ腫;AIDS関連リンパ腫;およびワルデンストレームマクログロブリン血症;慢性リンパ性白血病(CLL);急性リンパ芽球性白血病(ALL);有毛細胞白血病;慢性骨髄芽球性白血病;ならびに他の癌腫および肉腫;および移植後リンパ増殖性疾患(PTLD)、ならびに母斑症、浮腫(例えば、脳腫瘍に関連するもの)に関連する異常な血管増殖、ならびにメイグズ症候群である、請求項25〜29のいずれか一項に記載の方法。
- 前記患者が、中年である、請求項19〜30のいずれか一項に記載の方法。
- 前記患者が、約36歳〜約55歳である、請求項31に記載の方法。
- 前記患者が、高齢である、請求項19〜30のいずれか一項に記載の方法。
- 前記患者が、約56歳〜約85歳である、請求項33に記載の方法。
- 前記患者が、約18歳より前に、約16歳より前に、約14歳より前に、約12歳より前に、約10歳より前に、約8歳より前に、約6歳より前に、約4歳より前に、または約2歳より前に前記癌治療を受けた、請求項25〜34のいずれか一項に記載の方法。
- 前記TLR5アゴニストが、前記患者が前記癌治療を受けた後で少なくとも1週間、または少なくとも1ヶ月間、または少なくとも6ヶ月間、または少なくとも1年間、または少なくとも2年間、または少なくとも3年間、または少なくとも4年間、または少なくとも5年間前記患者に投与される、請求項25〜35のいずれか一項に記載の方法。
- 前記患者が、もはや癌を有していないかまたは前記患者が、前記TLR5アゴニストが投与される時点で寛解している、請求項25〜36のいずれか一項に記載の方法。
- 前記患者に前記TLR5アゴニストを投与することが、細胞老化を減少させることにより前記加齢性疾患または障害を治療または防止する、請求項19〜37のいずれか一項に記載の方法。
- 前記TLR5アゴニストが、フラジェリンまたはその誘導体である、請求項19〜38のいずれか一項に記載の方法。
- 前記TLR5アゴニストが、配列番号1に対して少なくとも95%の配列同一性を有するアミノ酸配列を有するポリペプチドを含む、請求項39に記載の方法。
- 前記TLR5アゴニストが、配列番号1であるアミノ酸配列を有するポリペプチドを含む、請求項40に記載の方法。
- 前記TLR5アゴニストが、配列番号2〜27の1つに対して少なくとも95%の配列同一性を有するアミノ酸配列を有するポリペプチドを含む、請求項39に記載の方法。
- 前記TLR5アゴニストが、配列番号2〜27の1つであるアミノ酸配列を有するポリペプチドを含む、請求項42に記載の方法。
- 前記患者の生物学的性別が、男性である、請求項19〜43のいずれか一項に記載の方法。
- 前記患者の生物学的性別が、女性である、請求項19〜43のいずれか一項に記載の方法。
- 前記TLR5アゴニストが、1つ以上のサイクルで投与される、請求項1〜45のいずれか一項に記載の方法。
- 前記サイクルが、1日1回を1日、1日1回を2日間、1日1回を3日間、1日1回を4日間、または1日1回を5日間患者に投与することを伴う、請求項46に記載の方法。
- 5サイクル以下、または3サイクル以下、または2サイクル以下が、年あたり投与される、請求項47に記載の方法。
- 虚弱の治療または防止における使用のためのTLR5アゴニスト。
- 虚弱の治療または防止のための医薬品の製造におけるTLR5アゴニストの使用。
- 加齢性疾患または障害の治療または防止における使用のためのTLR5アゴニスト。
- 加齢性疾患または障害の治療または防止のための医薬品の製造におけるTLR5アゴニストの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662028P | 2018-04-24 | 2018-04-24 | |
US62/662,028 | 2018-04-24 | ||
PCT/US2019/028911 WO2019209949A1 (en) | 2018-04-24 | 2019-04-24 | Methods for improving frailty and aging |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021522271A true JP2021522271A (ja) | 2021-08-30 |
JPWO2019209949A5 JPWO2019209949A5 (ja) | 2022-05-02 |
Family
ID=68295813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020560271A Pending JP2021522271A (ja) | 2018-04-24 | 2019-04-24 | 虚弱および加齢を改善するための方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210236594A1 (ja) |
JP (1) | JP2021522271A (ja) |
CN (1) | CN112203675A (ja) |
AU (1) | AU2019261592A1 (ja) |
CA (1) | CA3097989A1 (ja) |
EA (1) | EA202092530A1 (ja) |
SG (1) | SG11202010485VA (ja) |
WO (1) | WO2019209949A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3148988A1 (en) * | 2019-08-02 | 2021-02-11 | The General Hospital Corporation | Targeting the gastrointestinal barrier to treat age-related disorders |
WO2022093763A1 (en) * | 2020-10-29 | 2022-05-05 | Edifice Health, Inc. | Methods and compositions for diagnosing and treating frailty |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007513183A (ja) * | 2003-12-02 | 2007-05-24 | クリーブランド クリニック ファウンデイション | フラジェリンを使用して放射線から保護する方法 |
US20160083437A1 (en) * | 2012-11-30 | 2016-03-24 | Industry Foundation Of Chonnam National University | Composition comprising recombinant fusion protein of pathogenic antigen protein and flagellin of vibrio vulnificus for preventing, alleviating, or treating aging |
JP2017523180A (ja) * | 2014-07-30 | 2017-08-17 | クリーブランド バイオラブズ,インコーポレイテッド | フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580321B2 (en) * | 2003-12-02 | 2013-11-12 | The Cleveland Clinic Foundation | Method for reducing the effects of chemotherapy using flagellin related polypeptides |
US8007812B2 (en) * | 2004-12-22 | 2011-08-30 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
KR20070095338A (ko) * | 2004-12-24 | 2007-09-28 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 간기능 개선제 |
WO2007133076A2 (en) * | 2006-05-15 | 2007-11-22 | Erasmus Mc | Mannitol and/or proline for prevention and treatment of ageing related symptoms |
WO2016109002A2 (en) * | 2014-10-16 | 2016-07-07 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
-
2019
- 2019-04-24 SG SG11202010485VA patent/SG11202010485VA/en unknown
- 2019-04-24 JP JP2020560271A patent/JP2021522271A/ja active Pending
- 2019-04-24 WO PCT/US2019/028911 patent/WO2019209949A1/en unknown
- 2019-04-24 US US17/049,720 patent/US20210236594A1/en not_active Abandoned
- 2019-04-24 CA CA3097989A patent/CA3097989A1/en active Pending
- 2019-04-24 AU AU2019261592A patent/AU2019261592A1/en not_active Abandoned
- 2019-04-24 EA EA202092530A patent/EA202092530A1/ru unknown
- 2019-04-24 CN CN201980035285.3A patent/CN112203675A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007513183A (ja) * | 2003-12-02 | 2007-05-24 | クリーブランド クリニック ファウンデイション | フラジェリンを使用して放射線から保護する方法 |
US20160083437A1 (en) * | 2012-11-30 | 2016-03-24 | Industry Foundation Of Chonnam National University | Composition comprising recombinant fusion protein of pathogenic antigen protein and flagellin of vibrio vulnificus for preventing, alleviating, or treating aging |
JP2017523180A (ja) * | 2014-07-30 | 2017-08-17 | クリーブランド バイオラブズ,インコーポレイテッド | フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用 |
Non-Patent Citations (3)
Title |
---|
EXPERIMENTAL & MOLECULAR MEDICINE, vol. 49, no. 9, JPN6023020005, 2017, pages 373, ISSN: 0005216589 * |
EXPERIMENTAL GERONTOLOGY, vol. 87, JPN6023020004, 2017, pages 160 - 167, ISSN: 0005216588 * |
PLOS ONE, vol. 9, no. 1, JPN6023020003, 2014, pages 85587, ISSN: 0005216590 * |
Also Published As
Publication number | Publication date |
---|---|
CN112203675A (zh) | 2021-01-08 |
US20210236594A1 (en) | 2021-08-05 |
WO2019209949A1 (en) | 2019-10-31 |
EA202092530A1 (ru) | 2021-02-01 |
SG11202010485VA (en) | 2020-11-27 |
CA3097989A1 (en) | 2019-10-31 |
AU2019261592A1 (en) | 2020-11-19 |
EP3784263A1 (en) | 2021-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Roy et al. | Sphingosine 1-phosphate receptor modulators for multiple sclerosis | |
Odaira et al. | Mechanisms underpinning AMP-activated protein kinase-related effects on behavior and hippocampal neurogenesis in an animal model of depression | |
Xue et al. | Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis | |
Dutra | Kinin receptors: Key regulators of autoimmunity | |
JP2017200927A (ja) | ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 | |
JP2017081930A (ja) | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 | |
US20140178366A1 (en) | Preselection of subjects for therapeutic treatment based on hypoxic status | |
EA033573B1 (ru) | Комбинированное лечение меланомы, включающее введение кобиметиниба и вемурафениба | |
HUE032754T2 (en) | CSF-1R inhibitors for the treatment of brain tumors | |
TWI794885B (zh) | 全身紅斑性狼瘡之治療 | |
JP7001599B2 (ja) | 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法 | |
BR112019017851A2 (pt) | método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo | |
WO2019126739A1 (en) | Pyrvinium pamoate anti-cancer therapies | |
KR20200014790A (ko) | 난소암의 치료에 사용되는 티노스타무스틴 | |
ES2655291T3 (es) | Uso de cladribina para tratar neuromielitis óptica | |
US20170326200A1 (en) | Method of Treating Prader-Willi Syndrome | |
JP2006519823A (ja) | 疼痛治療のための化合物 | |
KR20180004818A (ko) | 염증성 장 질환의 치료를 위한 모델, 방법 및 조성물 | |
JP2021522271A (ja) | 虚弱および加齢を改善するための方法 | |
Li et al. | Deletion of Mst1 attenuates neuronal loss and improves neurological impairment in a rat model of traumatic brain injury | |
US11464786B2 (en) | CXCR7 inhibitors for the treatment of cancer | |
US20130289023A1 (en) | Method for treating brain tumor | |
DK2735316T3 (en) | New therapeutic approaches to treat neuroinflammatory conditions | |
JP2013535694A (ja) | 神経病理学的疾患の検出および調節におけるtam受容体およびtam受容体リガンド | |
KR101901001B1 (ko) | PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220421 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230523 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231212 |